Transfusion Medicine Reviews
Volume 24 , Pages S1-S6 , January 2010

Guidelines for the Use of Immunoglobulin Therapy for Primary Immune Deficiency and Solid Organ Transplantation

References 

  1. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(suppl 1):S9–S56
  2. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(suppl 1):S57–S107
  3. Hume HA, Anderson DR. Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev. 2007;21(suppl 1):S1–S2
  4. www.blood.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/resources/Fractionation/$file/1_00-05_en.pdf2009;Accessed August
  5. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomized placebo controlled trial. Lancet Neurol. 2008;7:136–144
  6. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev. 2003;17:241–251
  7. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–542
  8. Canadian Task Force on Preventative Health Care Levels of Evidence and Recommendation Guide. Available at http://www.ctfphc.org/. (Last accessed August 2009).

 STATEMENT OF CONFLICT OF INTEREST: Funding support from the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products.

 Publication funding: Canadian Blood Services Ottawa, Ontario, Canada.

PII: S0887-7963(09)00089-3

doi: 10.1016/j.tmrv.2009.09.009

Transfusion Medicine Reviews
Volume 24 , Pages S1-S6 , January 2010

Article Tools

* Image Usage & Resolution